Skip to main content

ORIGINAL RESEARCH article

Front. Public Health
Sec. Life-Course Epidemiology and Social Inequalities in Health
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1398803

Long-term distress throughout one's life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in China

Provisionally accepted
Wanxian Liang Wanxian Liang 1,2Shihuan Cao Shihuan Cao 1,2Yusi Suo Yusi Suo 1,2*Lining Zhang Lining Zhang 1,2*Lujia Yang Lujia Yang 1,2*Ping Wang Ping Wang 1,2Hanfei Wang Hanfei Wang 1,2*Han Wang Han Wang 1,2*Guannan Bai Guannan Bai 3Qingnan Li Qingnan Li 4,5*Jiayin Zheng Jiayin Zheng 4,5*Xuejing Jin Xuejing Jin 1,2*
  • 1 Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
  • 2 International Institute of evidence-based traditional Chinese medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
  • 3 Children’s Hospital, Zhejiang University School of Medicine, National Children’s Regional Medical Center, National Clinical Research Center for Child Health, Hangzhou, China
  • 4 Beijing Society of Rare Disease Clinical Care and Accessibility, Beijing, China
  • 5 China Alliance for Rare Diseases, Beijing, China

The final, formatted version of the article will be published soon.

    Introduction Neurofibromatosis type 1 (NF1) is a rare genetic disorder, with lack of evidence of disease burden in China. We aimed to describe the economic burden, health-related quality of life (HRQL), and caregiver burden of NF1 patients in China. Methods We conducted an online cross-sectional survey employing the China Cloud Platform for Rare Diseases, with 223 caregivers of NF1 pediatric patients (patients under 18), and 226 adult patients. Economic burden was estimated using direct and indirect costs related to NF1 in 2021, and the Work Productivity and Activity Impairment Questionnaire: General Health V2.0 (WPAI-GH). HRQL measures included EQ-5D-Y proxy version and PedsQLTM 4.0 Generic Core Scales (PedsQL GCS) proxy version for pediatric patients, and EQ-5D-5L and PedsQLTM 3.0 Neurofibromatosis Module (PedsQL NFM) for adult patients. Caregiver burden was estimated by Zarit Burden Interview (ZBI). Results For pediatric patients, the average direct cost in 2021 was CNY 33,614 (USD 4,879), and employed caregivers’ annual productivity loss was 81 days. EQ-5D-Y utility was 0.880±0.13 and VAS score was 75.38±20.67, with 52.6% patients reporting having problems in “pain/discomfort” and 42.9% in “anxiety/depression”. PedsQL GCS total score was 68.47±19.42. ZBI score demonstrated that 39.5% of caregivers had moderate-to-severe or severe burden. For adult patients, average direct cost in 2021 was CNY 24,531 (USD 3,560). Patients in employment reported an absenteeism of 8.5% and presenteeism of 21.6% according to the results of WPAI-GH. EQ-5D-5L utility was 0.843±0.17 and VAS score was 72.32±23.49, with more than half of patients reporting having problems in “pain/discomfort” and “anxiety/depression” dimensions. PedsQL NFM total score was 68.40±15.57. Conclusion Both pediatric and adult NF1 patients in China had a wide-ranging economic burden and low HRQL, especially in the psychological dimension. Caregivers for NF1 pediatric patients experienced considerable caregiver burden. More attention and support from policymakers and stakeholders are required to relieve NF1 patients’ and caregivers’ distress.

    Keywords: Neurofibromatosis type 1 (NF1), caregiver burden, economic burden, EQ-5D, health-related quality of life (HRQL). Word counts: 4562, Table counts: 7, Figure counts: 5

    Received: 10 Mar 2024; Accepted: 07 Aug 2024.

    Copyright: © 2024 Liang, Cao, Suo, Zhang, Yang, Wang, Wang, Wang, Bai, Li, Zheng and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yusi Suo, Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
    Lining Zhang, Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
    Lujia Yang, Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
    Hanfei Wang, Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
    Han Wang, Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
    Qingnan Li, Beijing Society of Rare Disease Clinical Care and Accessibility, Beijing, China
    Jiayin Zheng, China Alliance for Rare Diseases, Beijing, China
    Xuejing Jin, Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.